Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 12/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | GRK5 | P34947 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765223 | 1.00 | PIK3C3 (1.00) | PIK3C3NUDT1ROCK1IKBKBCHUK | |
| SCHEMBL20765331 | 0.79 | PIK3C3 (0.66) | PIK3C3ROCK1IKBKBCHUKROCK2 | |
| SCHEMBL20765196 | 0.75 | PIK3C3 (0.60) | PIK3C3NUDT1ROCK1IKBKBCHUK | |
| SCHEMBL30380778 | 0.75 | PIK3C3 (0.60) | PIK3C3NUDT1ROCK1IKBKBCHUK | |
| SCHEMBL23272166 | 0.72 | PIK3C3 (0.68) | PIK3C3 | |
| SCHEMBL20783062 | 0.72 | NUDT1 (0.61) | PIK3C3NUDT1ROCK1IKBKBCHUK | |
| SCHEMBL29670153 | 0.69 | PIK3C3 (0.53) | PIK3C3IKBKBCHUKJAK2JAK3 | |
| SCHEMBL20765217 | 0.69 | PIK3C3 (0.53) | PIK3C3IKBKBCHUKJAK2JAK3 | |
| SCHEMBL23891853 | 0.69 | PIK3C3 (0.52) | PIK3C3NUDT1ROCK1IKBKBCHUK | |
| SCHEMBL26503432 | 0.68 | PIK3C3 (0.51) | PIK3C3IKBKBCHUKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117241800-A | Antiviral Activity of VPS34 inhibitors | 德西费拉制药有限责任公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | claimed |
| EP-4251156-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| CN-111247144-B | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022115543-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4251156-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116589461-A | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111247144-B | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220184054-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | disclosed |
| WO-2022115543-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | PIK3C3 1407/4885NUDT1 1897/4885ROCK1 1603/4885 |
| US-20220184054-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885NUDT1 2755/4885ROCK1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.